First Implantation of Rega™ Family Implantable Pacemakers in China

Shanghai, China – The first batch of Rega™ Family Implantable Pacemakers has been implanted in several hospitals of Hubei, Guangdong, Shanghai, Shandong, Shaanxi, and Zhejiang provinces to help patients with bradycardia resume normal life and activities.
The domestically made pacemakers have world-class quality – its production strictly follow the International Quality Management System for Medical Devices (ISO13485) - but are 20% to 30% cheaper than the imported ones. Rega™ Family Implantable Pacemakers have three series (Orchidee™, Trefle™, and Rega™) with a total of eight models to meet the needs of various patients. They are all automatic, physiologic pacing pacemaker devices that feature small size and long life span. Specifically, they are the smallest pacemakers available in market with only eight cubic centimeters in volume, and they have service life of 10 to 12 years.
The launch and first application of Rega™ Family Implantable Pacemakers are supported by the Heart Rhythm Special Committee of Chinese Medical Doctor Association and Chinese Society of Pacing and Electrophysiology. Several industry experts said they looked forward to seeing the domestically made pacemakers benefit more Chinese patients with its world-class quality, relatively affordable price, and good after-sale service.
Currently, implanting pacemakers is the only effective way to reduce mortality and improve life quality of patients with bradycardia. There are around one million patients suffering from bradycardia in China with an estimated 300,000 to 400,000 new cases annually. However, due to lack of core technologies and industrialization experience, China almost solely relies on imports for pacemaker devices, the high price of which has deterred most patients with only 80,000 of them can be treated with pacemakers each year.
MicroPort Sorin CRM (Shanghai) Co., Ltd. ("MSC") was jointly founded by MicroPort® and Sorin Group in 2014 to develop and market "China made and China innovated" CRM devices. In November 2017, MicroPort Scientific Corporation announce that it is expected to acquire the CRM Business Franchise from LivaNova PLC (NASDAQ:LIVN) ("LivaNova") and upon completion of the acquisition, MicroPort® will become the most advanced domestic company in China with CRM know-how in the global CRM market. MSC will continue to serve the China market and develop CRM devices for the Chinese patients to help promote the development of CRM market in China.